116 Views | 36 Downloads
Byron B. Au-Yeung, byron.au-yeung@emory.edu
J.E. and B.B.A.-Y. conceptualized the study. J.E., W.Z.-K., and Y.H. performed experiments. J.E., W.Z.-K., and C.D.S. analyzed the RNA-sequencing data. K.S. and Y.H. designed and performed the tension probe experiments. Y.-L.T. and A.W. contributed conceptual input and provided Sts1−/− and Cbl-b−/− cells. J.E. and B.B.A.-Y. wrote the manuscript with input from all authors.
We thank Simon Grassmann and Wan-Lin Lo for critical reading of the manuscript, the Pediatric/Winship Flow Cytometry Core for cell sorting and the Emory Integrated Genomics Core (EIGC) for RNA-sequencing. This work was supported in part by the National Institute of Allergy and Infectious Diseases R01AI165706 (to B.B.A-Y.), NCI T32 CA108462-17 (Y.-L.T.) and Cancer Research Institute Irvington Postdoctoral Fellowship (Y.-L.T.).
A.W. is a co-founder and a scientific advisory board member of Nurix Therapeutics, Inc., which has a Cbl-b inhibitor in phase 1 clinical trials. A.W. owns stock and receives consulting fees from Nurix. No other disclosures were reported.